KIT and gastrointestinal stromal tumor: The associations between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and IDO expression indicate, that the combination of the KIT blockade with an anti-CTLA-4 therapy seems to be an effective approach in the management GIST (Table 1) [103].